27.34
price down icon1.16%   -0.32
after-market Dopo l'orario di chiusura: 27.34
loading
Precedente Chiudi:
$27.66
Aprire:
$27.38
Volume 24 ore:
680.87K
Relative Volume:
1.02
Capitalizzazione di mercato:
$1.60B
Reddito:
$32.87M
Utile/perdita netta:
$674.31M
Rapporto P/E:
2.4067
EPS:
11.36
Flusso di cassa netto:
$-330.11M
1 W Prestazione:
-0.65%
1M Prestazione:
-12.65%
6M Prestazione:
-40.12%
1 anno Prestazione:
-7.42%
Intervallo 1D:
Value
$26.91
$28.02
Intervallo di 1 settimana:
Value
$26.86
$28.38
Portata 52W:
Value
$23.41
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
Nome
Agios Pharmaceuticals Inc
Name
Telefono
617-649-8600
Name
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Name
Dipendente
488
Name
Cinguettio
@AgiosPharma
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
AGIO's Discussions on Twitter

Confronta AGIO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
27.34 1.60B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-24 Iniziato H.C. Wainwright Buy
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-10-10 Ripresa Raymond James Outperform
2024-09-27 Downgrade Leerink Partners Outperform → Market Perform
2024-02-08 Iniziato Cantor Fitzgerald Overweight
2023-02-03 Iniziato Piper Sandler Overweight
2022-11-17 Aggiornamento Goldman Sell → Neutral
2022-07-27 Aggiornamento SVB Leerink Mkt Perform → Outperform
2021-12-03 Iniziato BofA Securities Buy
2021-07-30 Downgrade Goldman Neutral → Sell
2021-07-01 Iniziato Raymond James Mkt Perform
2021-06-10 Iniziato H.C. Wainwright Buy
2021-03-01 Downgrade JP Morgan Overweight → Neutral
2021-03-01 Aggiornamento SVB Leerink Mkt Perform → Outperform
2021-02-26 Downgrade SVB Leerink Outperform → Mkt Perform
2020-10-22 Aggiornamento Barclays Equal Weight → Overweight
2020-03-04 Iniziato Barclays Equal Weight
2019-11-26 Iniziato Cantor Fitzgerald Overweight
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
2019-05-23 Ripresa Goldman Neutral
2019-02-15 Aggiornamento SVB Leerink Mkt Perform → Outperform
2018-09-25 Iniziato Leerink Partners Mkt Perform
2018-05-23 Iniziato Citigroup Buy
2018-04-11 Reiterato Credit Suisse Outperform
2018-02-15 Reiterato Needham Buy
2018-02-15 Reiterato SunTrust Buy
2017-09-15 Iniziato RBC Capital Mkts Outperform
2017-08-10 Reiterato Needham Buy
2017-08-08 Reiterato SunTrust Buy
2017-08-02 Aggiornamento Leerink Partners Mkt Perform → Outperform
2017-06-26 Downgrade Janney Buy → Neutral
2017-01-17 Aggiornamento Oppenheimer Perform → Outperform
2016-10-24 Iniziato Needham Buy
2016-06-13 Aggiornamento JP Morgan Neutral → Overweight
2016-05-18 Reiterato SunTrust Buy
Mostra tutto

Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie

pulisher
Apr 17, 2025

BofA Adjusts Price Target on Agios Pharmaceuticals to $52 From $54, Keeps Buy Rating - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Agios Pharmaceuticals (AGIO) Price Target Lowered by BofA but Buy Rating Maintained | AGIO Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 | AGIO Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Agios Pharmaceuticals to Host Conference Call for Q1 2025 Financial Results on May 1, 2025 - Nasdaq

Apr 17, 2025
pulisher
Apr 17, 2025

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 - TradingView

Apr 17, 2025
pulisher
Apr 14, 2025

Anemia Market Set to Witness Significant Growth by 2032, Driven by Rising Awareness and Novel Oral Alternatives | DelveInsight - Barchart.com

Apr 14, 2025
pulisher
Apr 12, 2025

Trexquant Investment LP Increases Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Apr 12, 2025
pulisher
Apr 10, 2025

Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock By Investing.com - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock - Investing.com Australia

Apr 10, 2025
pulisher
Apr 10, 2025

Agios Pharmaceuticals Director Sells Shares to Cover Tax Obligations - TradingView

Apr 10, 2025
pulisher
Apr 08, 2025

Agios stock touches 52-week low at $24.33 amid market challenges - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Agios stock touches 52-week low at $24.33 amid market challenges By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 03, 2025

Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says - MarketScreener

Apr 03, 2025
pulisher
Apr 01, 2025

Agios stock touches 52-week low at $27.12 amid market shifts - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Agios stock touches 52-week low at $27.12 amid market shifts By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Mar 26, 2025

Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey

Mar 26, 2025
pulisher
Mar 26, 2025

10 Best Small-Cap Stocks to Buy Before They Explode - Insider Monkey

Mar 26, 2025
pulisher
Mar 24, 2025

First Week of November 21st Options Trading For Agios Pharmaceuticals (AGIO) - Nasdaq

Mar 24, 2025
pulisher
Mar 21, 2025

Agios Pharmaceuticals divulges new PAH stabilizers for phenylketonuria - BioWorld MedTech

Mar 21, 2025
pulisher
Mar 19, 2025

Beta Thalassemia Market Predicted to See Upsurge Through 2034, - openPR

Mar 19, 2025
pulisher
Mar 12, 2025

Agios Pharmaceuticals at Barclays Conference: Strategic Advances in Rare Disease Treatments - Investing.com UK

Mar 12, 2025
pulisher
Mar 11, 2025

Agios Pharm at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 10, 2025

Q1 EPS Estimate for Agios Pharmaceuticals Lowered by Analyst - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

FY2027 Earnings Estimate for AGIO Issued By Zacks Research - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

Agios Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer - The Manila Times

Mar 06, 2025
pulisher
Mar 05, 2025

Agios Pharmaceuticals Announces Inducement Equity Awards for New Executive - GuruFocus.com

Mar 05, 2025
pulisher
Mar 05, 2025

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate - EIN News

Mar 05, 2025
pulisher
Mar 05, 2025

Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences - Barchart

Mar 05, 2025
pulisher
Mar 05, 2025

Meet Agios' New Strategy Chief: Inside the $2M+ Executive Compensation Deal - Stock Titan

Mar 05, 2025
pulisher
Mar 04, 2025

Agios Pharmaceuticals chief commercial officer sells $59,742 in stock By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Agios Pharmaceuticals chief commercial officer sells $59,742 in stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Agios Pharmaceuticals CEO sells shares worth $460,135 - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Agios to Present at Upcoming Investor Conferences - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

Where to Hear Agios Management Next Month: Key Investor Conferences Revealed - StockTitan

Mar 04, 2025
pulisher
Mar 01, 2025

Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune

Mar 01, 2025
pulisher
Mar 01, 2025

Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now? - Insider Monkey

Mar 01, 2025
pulisher
Mar 01, 2025

Y Intercept Hong Kong Ltd Acquires Shares of 45,817 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

What is HC Wainwright's Estimate for AGIO Q1 Earnings? - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Earnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock rises - MSN

Feb 28, 2025
pulisher
Feb 28, 2025

10 Best Small-Cap Stocks to Buy Now - Insider Monkey

Feb 28, 2025
pulisher
Feb 28, 2025

Gilbert Cisneros conducts multiple transactions in stocks including Agios Pharmaceuticals and Airbnb - MSN

Feb 28, 2025
pulisher
Feb 27, 2025

Sickle Cell Disease Market Growth Projections 2024-2034: - openPR

Feb 27, 2025
pulisher
Feb 27, 2025

Q4 Earnings Estimate for AGIO Issued By HC Wainwright - MarketBeat

Feb 27, 2025
pulisher
Feb 26, 2025

Venturi Wealth Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Feb 26, 2025
pulisher
Feb 26, 2025

What is HC Wainwright’s Estimate for AGIO Q4 Earnings? - Defense World

Feb 26, 2025
pulisher
Feb 26, 2025

Agios Bolsters Coffers With $1.1 Bln Milestone Payments Following FDA Approval Of Vorasidenib - RTTNews

Feb 26, 2025
pulisher
Feb 24, 2025

H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 24, 2025

H.C. Wainwright starts Agios Pharmaceuticals coverage with 'buy' - TradingView

Feb 24, 2025
pulisher
Feb 24, 2025

H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating - Investing.com India

Feb 24, 2025
pulisher
Feb 21, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 6.0% in January - MarketBeat

Feb 21, 2025

Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Capitalizzazione:     |  Volume (24 ore):